Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Sera Prognostics, Inc.NASDAQ: SERA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $8.77M (cash outflow) rose 16.2% year over year, ahead of the +0.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 43.4% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.

Context

  • Operating cash flow amounted to 31633.3% of revenue in FY2025, up 13206.1 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +16.2% holds above the trailing-twelve-month pace of +0.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.77M+43.4% QoQ
Last fiscal yearDec 2025
-$25.62M+80.6% YoY
LTMMar 2026
-$26.84M+0.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.2%——
1 year+80.6%——
3-year CAGR-9.5%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(25.62M) USD
Year-over-year change
-80.6%

Operating Cash Flow vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.4% is the 5th highest of 8, against a peer median of +4.8%.
  • Operating cash flow amounts to 47094.7% of revenue for SERA, versus a peer median of 446.5%.
SERA Competitors
Operating Cash Flow for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$46.12M USD+4.8%+16.1%898.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$36.18M USD-4.0%-19.0%105.2%
SRZNSurrozen, Inc.LTM Mar 2026$33.46M USD+84.2%-11.8%446.5%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$30.89M CAD+18.8%+5.7%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.3M USD—+54.4%—
SERASera Prognostics, Inc.LTM Mar 2026$26.84M USD+0.4%-9.5%47094.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$20.25M USD-34.9%+9.9%—
STSSSkyAI, Inc.LTM Mar 2026$16.95M USD+126.2%+37.5%4269.4%
APYXApyx Medical CorporationLTM Mar 2026$7.87M USD-36.6%-26.7%14.1%
Peer median (excluding SERA) —+4.8%+7.8%446.5%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Depreciation & Amortization659K756K900K833K940K
Deferred Income Tax00000
Stock-Based Compensation3.13M5.06M5.27M7.01M5.11M
Change in Working Capital(44K)3.55M3.52M11.28M(546K)
Accounts Receivables(3.14M)(2.97M)(5.36M)11.42M22K
Inventory00000
Accounts Payables603K352K(442K)455K(1.01M)
Other Working Capital2.49M6.17M9.32M(597K)441K
Other Non-Cash Items(372K)213K(638K)(412K)801K
Operating Cash Flow(31.64M)(34.61M)(27.19M)(14.19M)(25.62M)
Capital Expenditures(1.3M)(791K)(128K)(1.1M)(726K)
Acquisitions (Net)00000
Purchases of Investments(82.06M)(48.07M)(54.14M)(35.83M)(87.61M)
Sales of Investments800K54.4M54.4M48.68M59.84M
Other Investing Activities016K311K(1.05M)0
Investing Cash Flow(82.56M)5.55M438K11.74M(28.5M)
Debt Repayment(7.66M)(303K)(466K)(440K)(194K)
Common Stock Issued66.61M00054.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.66M308K1.22M3.05M0
Financing Cash Flow159.59M5K752K2.61M54.03M
Effect of Forex Changes00000
Net Change in Cash45.4M(29.05M)(26M)163K(99K)
Free Cash Flow(32.94M)(35.4M)(27.32M)(15.29M)(26.35M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.